This 5½-minute video describes the application of PROMIS measures in a clinical setting for patients suffering from gastro-intestinal distress.
Applications in Clinical Practice
HealthMeasures are increasingly being used in clinical settings. They provide clinicians with efficient, reliable, and valid assessments of adult and child health, including function, symptoms, feelings and perceptions.
Evidence Supporting Routine Collection of Patient-Reported Outcomes (PROs)
There is a growing body of evidence on the impact of routinely collecting PROs (like those in PROMIS®, Neuro-QoL, ASCQ-Me®, and NIH Toolbox® Emotion) in clinical practice.
- A 2013 systematic review of this literature found three benefits of the clinical use of PROs: improved patient-provider communication, patient satisfaction, and detection of unrecognized problems. The evidence has not accumulated for the impact of PROs on changes in patient management, patient behavior, health outcomes, nor improvement in quality of healthcare.
- A 2015 review confirmed the finding that routine collection of PROs improved communication about symptoms and quality of life.
- A 2016 study at Memorial Sloan Kettering Cancer Center found that patients with advanced cancer who completed PROs on 12 common symptoms had “better health-related quality of life, fewer ER visits, fewer hospitalizations, a longer duration of palliative chemotherapy, and superior quality –adjusted survival” (p. 562). A 2019 study with a similar intervention with patients with lung cancer also found increased survival.
- However, a 2018 randomized controlled trial in general internal medicine and family practice clinics found that simply sharing PROMIS scores with clinicians did not reduce fatigue, sleep disturbance, pain interference, anxiety, or depression more than usual care.
HealthMeasures Are Included in Clinical Guidelines
- The North South Wales Agency for Clinical Innovation published a report on using patient reported outcomes in the integrated care context. Based on a 2013 review, PROMIS measures were included in a recommended short-list of PRO measures. The report states, “After review of the evidence there was strong evidence to support PROMIS.”
- PROMIS measures are included in The American College of Rheumatology’s 2015 Guidelines for the Treatment of Rheumatoid Arthritis.